modakafusp alfa + bortezomib

Modakafusp alfa + bortezomib is a combination regimen under clinical investigation for the treatment of relapsed/refractory multiple myeloma. **Modakafusp alfa** is a novel immunocytokine composed of a humanized anti-CD38 immunoglobulin G4 antibody fused to two attenuated interferon alfa-2b molecules. It is designed to target delivery of interferon alfa specifically to CD38-positive myeloma and immune cells, leading to direct myeloma cell death and broad activation of the innate and adaptive immune system[1][2][3][7]. This targeted interferon delivery stimulates the immune response, increases CD38 expression, and induces immune effector cell activation. **Bortezomib** is a well-established proteasome inhibitor that disrupts protein degradation within myeloma cells, resulting in apoptosis. The combination is being studied for its synergistic antimyeloma effect, leveraging direct cytotoxicity and immune modulation.

Other names

TAK-573 + bortezomib